Labetalol, a combined α 1 , β 1 , and β 2 adrenoceptor-blocking drug, has been shown to have analgesic properties in vivo. To determine the underlying mechanisms, we examined its effects on GABA A receptor-mediated spontaneous inhibitory postsynaptic currents (sIPSCs) and spontaneous firings of rat ventrolateral periaqueductal gray (PAG) neurons, either mechanically dissociated, or in acute brain slices. These PAG neurons mediate opioidmediated analgesia and pain transmission and are under tonic control of GABAergic interneurons. An increase in GABAergic transmission to these neurons yields an inhibitory hyperpolarized state and may interrupt pain signal transmission. Using patch clamp techniques, we found that labetalol reversibly increases the frequency of sIPSCs without changing their mean amplitude. This indicates that labetalol enhances GABAergic synaptic transmission by a presynaptic mechanism. Metoprolol, a specific β 1 -adrenoceptor antagonist, also reversibly enhanced sIPSC frequency. In the presence of metoprolol, labetalol-induced increase in sIPSC frequency was significantly attenuated or even abolished. These results suggest that labetalol shares the same pathway as metoprolol in enhancing GABAergic transmission via an inhibition of presynaptic β 1 -adrenoceptors. We further showed that labetalol reversibly reduced the firing rate of PAG neurons. This reduction was significantly attenuated in the presence of bicuculline, a selective antagonist of GABA A receptors. These data indicate that labetalol-induced inhibition of PAG cell firing is attributable to its potentiation of GABAergic transmission. Based on these data, we postulate that labetalolinduced analgesia is at least in part ascribed to its antagonistic effects on presynaptic β 1 -adrenoceptors.
Introduction
Labetalol is a potent antihypertensive agent. It exhibits selective α 1 -and nonselective β 1 -and β 2 -adrenergic antagonist effects (MacCarthy and Bloomfield, 1983) . In an in vivo animal study (Khanna et al., 1978) , using hot plate tests, it was found that intraperitoneal administration of labetalol enhanced the analgesic effects of morphine. These results imply the involvement of supraspinal mechanisms (Franklin and Abbott, 1989) . Moreover, labetalol has been used clinically to relieve pathological pain in humans (Margaria et al., 1983) . Although decades have passed, the mechanisms underlying labetalolinduced analgesia remain poorly understood.
The midbrain periaqueductal gray (PAG) is a major site of opioid and analgesic actions in the central nervous system (Vaughan et al., 1996) . It has been proposed that opioids produce antinociception in the PAG by directly inhibiting tonically active GABAergic interneurons, thereby disinhibiting the ventrolateral PAG output neurons which project to the rostral ventromedial medulla (RVM). Microinjection of morphine in the PAG increases activity of RVM Off-cells and decreases that of RVM On-cells. The activity of the former one increases, whereas that of the later stops, just prior to the initiation of nociceptive response (Heinricher et al., 1987) .
Norepinephrine is a neurotransmitter known to be involved in the ascending and descending pain transmission pathway (Cousins and Mather, 1984) . Several lines of evidence point to the possibility that norepinephrine functions within the PAG. 1) Both catecholamine-synthesizing enzymes: tyrosine hydroxylase (Pearson et al., 1983) and the norepinerphrinesynthesizing phenylethanolamine N-methyltransferase (Kopp et al., 1979) are expressed in the PAG. 2) Release-based studies have shown high concentrations of norepinephrine in the PAG (Behbehani, 1995) . 3) Epinephrine causes prolonged changes in the basal firing rate of PAG cells (Jiang et al., 1992) . 4) The existence of subtypes of adrenoceptors, including the α 1 - (Mitchell et al., 2003) , α 2 - (Mitchell et al., 2003; Peng et al., 1996; Vaughan et al., 1996) and β-adrenoceptors (Behbehani, 1995) has been found in the PAG.
As a major inhibitory neurotransmitter in the central nervous system, γ-aminobutyric acid (GABA) regulates the excitability of neurons, including those involved in the relay of pain signals (Jasmin et al., 2004) . Modulation of GABAergic synaptic transmission by norepinephrine was found in various preparations. These include: the anterior cerebral cortex, the thalamus and the hypothalamus (Kamisaki et al., 1992; Chong et al., 2004) , the cerebellum (Cheun and Yeh, 1996; Saitow et al., 2000) , the spinal cord (Baba et al., 2000) , the substantia nigra (Cathala et al., 2002) , the mesencephalic red nucleus (Ciranna et al., 2004) , and the bed nucleus of the stria terminals (Dumont and Williams, 2004) . However, it is unknown whether norepinephrine is also involved in the modulation of GABAergic synaptic transmission in the PAG.
In the present study, we hypothesized that labetalol disrupts adrenergic modulation of GABAergic function and thus increases inhibitory input to ventrolateral PAG neurons. Consequently, this would depress the activity of PAG cells and pain transmission. In the right column, photos of a fusiform (C) and a pyramidal (D) PAG neuron mechanically dissociated from the midbrain slice were obtained by a Leica DMIRB invert microscope (40× objective). The much-reduced dendritic arbors of such neurons facilitate the space clamp. These nerve-bouton preparations often preserve some functional synaptic boutons.
Results

Spontaneous GABAergic IPSCs (sIPSCs) recorded in mechanically dissociated PAG neurons
In the presence of 50 μM 5-amino-phosphonovalerate (APV), a competitive antagonist to glutamate N-methyl D-aspartate (NMDA) receptors and 20 μM 6,7-dinitroquinoxaline-2,3-dione (DNQX), an antagonist to α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors, high rates of spontaneous postsynaptic current (sPSCs) were recorded at the holding potential (V H ) of −50 mV, in the majority of the neurons mechanically dissociated from the ventrolateral region of PAG area (Fig. 1) . Most of these sPSCs were stable for more than 40 min. Application of 10 μM bicuculline (BIC), a selective GABA A receptor antagonist, completely and reversibly eliminated these sPSCs, indicating that they are GABA A R-mediated spontaneous inhibitory postsynaptic currents (sIPSCs) ( Fig. 2A, B) .
To determine the reversal potential of the sIPSCs, we measured their mean of peak amplitude (of 30 -60 s) at various V H levels from − 90 to +50 mV with an increment of 20 mV. In Fig. 2C , typical traces (10 s) are shown at various V H levels. These results confirm that sIPSCs, recorded in this preparation, were mediated by channels selectively permeable for Cl − . 
Effects of labetalol on sIPSC frequency of PAG neurons
The ventrolateral PAG output neurons are known to be under the tonic control of GABAergic inhibitory synapses (Behbehani, 1995) . To determine whether labetalol modulates GABAergic synaptic transmission of the PAG, we examined the effects of labetalol on sIPSCs of mechanically dissociated PAG neurons. The application of 1 nM labetalol (LAB) profoundly enhanced sIPSC frequency ( Fig. 3A, C ; by 41 ± 8%; from 1.42 ± 0.42 Hz in control to 1.88 ± 0.48 Hz in labetalol (n = 9 neurons, p < 0.001)). The increase in sIPSC frequency is further illustrated in Fig. 3B , on the left side, by the leftward shift of cumulative plots of the intervals between successive sIPSCs (inter-event interval). The corresponding plot, in Fig. 3B , on the right hand side, illustrates the lack of change in their amplitude (14 ± 8%; p = 0.89; n = 9). Fig. 3C illustrates the concentration-dependence of labetalol-induced changes of sIPSC frequency (left panel) and amplitude (right panel). The dose-response curve of labetalol-induced facilitation of sIPSC frequency was successfully fitted to a Logistic equation as defined in the Experimental procedures section, and an EC 50 of 1 nM was obtained. At a concentration of 10 nM, labetalol increased the sIPSC frequency by 83%. In contrast, labetalol (0.1 -10 nM) did not significantly alter the mean sIPSC amplitude (Fig. 3C, right panel) .
These data also suggest that there is some free catecholamine transmitter in this preparation. This possibility is further supported by the effect of prazosin (see below Fig. 4 ). Future study identifying the source of this catecholamine is warranted.
2.3.
Antagonist to β 1 -, but not α 1 -and β 2 -adrenoceptor, mimics the effects of labetalol on sIPSC frequency
Since there is tonic adrenergic innervation in our preparation, and labetalol is a combined α 1 -, β 1 -, and β 2 -adrenoceptorblocking drug, in the following experiments we attempted to determine which subtype(s) of adrenoceptors is responsible for labetalol-induced facilitation of sIPSCs in mechanically dissociated PAG neurons.
Prazosin (PRAZ, 10 μM, Fig. 4A 1 ) , an antagonist to α 1 -adrenoceptor, and butoxamine (BUTO, 2 μM, Fig. 4B 1 ) , a β 2 -adrenoceptor, both prominently decreased sIPSC frequency. It was further illustrated in Fig. 4A 2 and B 2 that both of them induced significant rightward shift of cumulative probability plots of inter-event intervals. On average, PRAZ and BUTO respectively suppressed sIPSC frequency by 48± 8% (from 1.24± 0.23 Hz in control to 0.70 ± 0.21 Hz in PRAZ, n =5, p = 0.002, inset in Fig. 4A 2 ) and 54± 2% (from 0.93± 0.14 Hz in control to 0.43± 0.08 Hz in BUTO, n =5, p = 0.001, inset in Fig. 4B 2 ).
Metoprolol (MET, 100 nM), a β 1 -adrenoceptor antagonist, reversibly raised the frequency of sIPSCs (Fig. 5A, B ). This effect was further illustrated in Fig. 5C , in which 100 nM metoprolol induced a significant leftward shift of the cumulative probability plot of inter-event intervals (K -S test, p < 0.001). On average, 100 nM metoprolol enhanced sIPSC frequency by 42± 6% (from 1.61 ± 0.39 Hz in control to 2.24± 0.56 Hz in metoprolol, n =9, p = 0.002, inset in Fig. 5C ), however, it did not change sIPSC amplitude (103 ± 4% of control, from 17.3 ± 2.1 in control to 17.7 ± 2.3 in metoprolol, n =9, p = 0.28, data not illustrated).
Metoprolol-induced enhancement of sIPSC frequency suggested that the activation of β 1 -adrenoceptor would decrease sIPSC frequency. To test this possibility, and due to the lack of specific β 1 -adrenoceptor agonist, we examined the effect of norepinephrine (NE), an agonist of α-and β-adrenoceptors, on sIPSC frequency in the presence of phentolamine (PHEN), an α-adrenoceptor antagonist, and butoxamine (BUTO), a β 2 -adrenoceptor antagonist. The application of 10 μM phentolamine and 2 μM butoxamine decreased sIPSC frequency by 33 ± 5% (from 1.25 ± 0.30 Hz in control to 0.96 ± 0.30 Hz in PHEN + BUTO, n = 6, p = 0.005, data not illustrated). At the newly established baseline, 10 μM norepinephrine further decreased sIPSC frequency ( Fig. 5D ) and induced a rightward shift of cumulative probability plot of inter-event intervals (K -S test: p < 0.01, Fig. 5E ). On average, 10 μM norepinephrine induced a decrease of 34 ± 2% in sIPSC frequency (0.66 ± 0.2 Hz in PHEN + BUTO + NE vs. 0.96 ± 0.30 Hz in PHEN + BUTO, n = 6, p = 0.0005, inset in Fig. 5E ). This result supports our hypothesis that activation of β 1 -adrenoceptor decreases sIPSC frequency.
2.4.
Labetalol enhances sIPSC frequency via an inhibition of β 1 -adrenoceptors
The above experiments imply that among the targeted adrenoceptors of labetalol, β 1 -adrenoceptor is most likely responsible for labetalol-induced facilitation of sIPSC frequency. To further test this possibility, we examined the effects of labetalol on sIPSCs recorded from mechanically dissociated neurons in the absence or the presence of metoprolol. The rationale for this series of experiments is that if labetalol and metoprolol acting on the same pathway in facilitating sIPSCs, they will compete with each other when they are applied together.
At a submaximal concentration (3 nM), labetalol prominently and reversibly increased sIPSC frequency (Fig. 6A-B ) by 69 ± 17% (from 1.61 ± 0.74 Hz in control, to 2.74 ± 0.96 Hz in labetalol, n = 5 neurons, p < 0.001, Fig. 6D ). Furthermore, labetalol induced a significant leftward shift of the cumulative probability plot of inter-event intervals (K -S test, p = 0.005, Fig. 6C, left panel) . Repeated application of labetalol increased sIPSC frequencies to a similar extent (data not shown). As expected, metoprolol (100 nM MET) also increased sIPSC frequency (Fig. 6A) . After the establishment of a stable baseline in the presence of 100 nM metoprolol, 3 nM labetalol increased sIPSC frequency (Fig. 6A-B ) by 18 ± 2% (from 1.83± 0.89 Hz (PHEN, 10 μM) , an α-adrenoceptor antagonist, and butoxamine (BUTO, 2 μM), a β 2 -adrenoceptor antagonist. (E) cumulative probability plots of inter-event interval of sIPSCs before (PHEN + BUTO) and during (+NE) the application of 10 μM NE. Inset, the summary from 6 neurons, of the effect of norepinephrine on sIPSC frequency in the presence of phentolamine PHEN and butoxamine. ** p < 0.01, PHEN + BUTO vs. PHEN + BUTO + NE. in metoprolol to 2.18 ± 0.98 Hz in LAB+MET, n =5 neurons, p< 0.01, Fig. 6D ) and induced a slight leftward shift of cumulative probability plot of inter-event intervals (Fig. 6C, right panel) . This effect (18 ± 2%) is significantly weaker than 69 ± 17% by labetalol alone (Fig. 6D , n =5 neurons, p = 0.02).
In the other 6 experiments, 3 nM labetalol reversibly increased sIPSC frequency (by 52± 10%; from 0.82± 0.25 Hz in control to 1.13± 0.30 Hz in labetalol, n = 6 neurons, p <0.001, data not illustrated). 10 μM metoprolol significantly increased sIPSC frequency (by 91± 19%, from 0.61± 0.19 Hz to 1.23± 0.37 Hz, n =6 neurons, p <0.001, data not illustrated). After a stable baseline was established in the presence of 10 μM metoprolol, the application of 3 nM labetalol did not induce a significant change in sIPSC frequency (a reduction of 15± 9%, from 1.23 ± 0.37 Hz in metoprolol to 1.02± 0.41 Hz in LAB + MET, n = 6 neurons, p >0.05, Fig. 6D ). This effect differs significantly from that in the absence of metoprolol (52 ± 10%, p <0.05, n = 6 neurons; Fig. 6D ).
These results suggest that labetalol and metoprolol compete for the same receptors. These results also suggest that β 1 -adrenoceptors mediate labetalol-induced facilitation of GABAergic transmission in the PAG cells.
2.5.
Labetalol inhibits the activity of PAG neurons in midbrain slices
Next, we examined the effects of labetalol on the activity of neurons in ventrolateral PAG in midbrain slices. Spontaneous action potential firing was recorded from current-clamped neurons (at 0 pA). As illustrated in Fig. 7A , 10 nM labetalol prominently and reversibly inhibited the spontaneous action potential firings. Spontaneous firing was noted to vary prior to labetalol administration. Therefore, labetalolinduced changes in firing rates are usually expressed as percentage change from control.
In 5 experiments, 10 nM labetalol inhibited the spontaneous firing rate by 63 ± 4% (from 3.07 ± 0.62 Hz in control to 1.19 ± 0.31 Hz in labetalol, p < 0.001, Fig. 7B, left panel) . The inhibition depended on the concentration of labetalol (Fig. 7B , left panel). 1 nM and 100 nM labetalol respectively inhibited the spontaneous firing rate by 36 ± 5% (from 3.64 ± 0.91 Hz in control to 2.51 ± 0.93 in 1 nM labetalol, n = 5, p = 0.01) and 56 ± 7% (from 4.93 ± 0.38 Hz in control to 2.19 ± 0.33 Hz in 100 nM labetalol, n = 4, p < 0.001).
The above experiments demonstrate that labetalol enhanced GABAergic sIPSCs (Fig. 3) and inhibited PAG neuron firing (Fig. 7A ). To determine whether there is a correlation between these two effects of labetalol, we compared the action of labetalol on the firing in the absence and the presence of bicuculline (BIC), a specific GABA A receptor antagonist. As illustrated in Fig. 7C and D, 10 μM bicuculline alone prominently facilitated the firing of the PAG neurons. This result indicates that these cells were under the tonic inhibition of GABAergic transmission in our experimental conditions. On average, 10 μM bicuculline increased the firing rate by 60± 19% (from 1.81± 0.22 Hz in control to 2.78± 0.34 Hz in BIC, n =6, p = 0.003). After a stable baseline was established, the application of 1 and 10 nM labetalol respectively inhibited the firing rate by 16± 4% (from 2.58± 0.31 Hz in BIC to 2.12± 0.13 Hz in 1 nM labetalol + BIC, n =5, p = 0.001) and 30± 6% (from 3.34± 0.47 Hz in BIC, 2.43 ± 0.43 Hz in 10 nM labetalol + BIC, n = 5, p = 0.000) (Fig. 7E) . These are significantly less than the changes in the absence of BIC (16 ± 4% in BIC vs. 36 ± 5% without BIC, n = 5, p < 0.001; 30 ± 6% in BIC, vs. 63 ± 4% without BIC, n =5, p <0.001, Fig. 7E ). These results suggest that the enhancement of sIPSCs at least partially contributes to labetalol-induced inhibition of the activity of PAG neurons.
Moreover, as illustrated in Fig. 7B (right panel), 1, 10 and 100 nM LAB significantly hyperpolarized the membrane: by 1.9 ± 0.5 mV (from 46.9 ± 0.7 mV in control to 48.8 ± 1.0 mV in 1 nM LAB, n =5, p = 0.01), by 4.4 ± 0.9 mV (from 49.1 ± 0.6 mV in control to 53.5 ± 1.1 mV in 10 nM LAB, n = 5, p = 0.004), and by 3.4 ± 0.2 mV (from 47.9 ± 1.7 mV in control to 51.2 ± 1.7 mV in 100 nM LAB, n = 5, p < 0.001), respectively.
Discussion
In the present study, using patch clamp recording from PAG neurons either isolated mechanically or in brain slices, we demonstrated that labetalol enhanced GABA release, via inhibition of β 1 -adrenoceptors. We then showed that labetalol reduced the spontaneous firings of PAG neurons, which may be attributable to its enhancement of GABA release. As PAG neurons play a critical role in pain transmission, our data might provide an explanation, for the cellular and molecular mechanisms, underlying labetalol-induced analgesic effects observed in vivo.
Several subtypes of adrenoceptors modulate GABA release onto PAG neurons
As described in the beginning of this report, adrenergic modulation of GABA release has been found in several brain regions (Kamisaki et al., 1992; Cathala et al., 2002; Ciranna et al., 2004; Dumont and Williams, 2004) . Although the existence of α 1 -, α 2 -, and β-adrenoceptors in the PAG has been found in several laboratories (Behbehani, 1995; Peng et al., 1996; Vaughan et al., 1996; Mitchell et al., 2003) , their roles in GABA release have not been reported. In the present study, we showed that an antagonist of the β 1 -adrenoceptor (metoprolol) enhanced, while those of α 1 -(prazosin) and β 2 -(butoxamine) adrenoceptor decreased GABAergic sIPSC frequency. The spontaneous postsynaptic currents are events that represent the release of presynaptic vesicles. A change in the frequency usually represents a presynaptic action (Li et al., 1998) . Our results suggest that α 1 -, β 1 -, and β 2 -adrenoceptors exist on GABAergic terminals which made synapses onto the PAG cells, and that activation of these presynaptic α 1 -and β 2 -adrenoceptors increases GABA release onto PAG neurons. This is consistent with previous reports on other brain regions (Baba et al., 2000; Chong et al., 2004; Dumont and Williams, 2004) . However, our data indicate that activation of β 1 -adrenoceptor suppressed GABAergic synaptic transmission to PAG neurons. This was further confirmed by norepinephrine-induced inhibition of sIPSC frequency in the presence of α-and β 2 -adrenoceptor antagonists.
Labetalol enhances GABAergic synaptic transmission by a presynaptic mechanism
In the present study, on mechanically dissociated PAG neurons, labetalol enhanced sIPSC frequency without changing their mean amplitude. As stated above, when a modulator produces a change in the frequency, but not the amplitude of sIPSCs, its action is at the presynaptic site (Li et al., 1998) . Our results suggest that labetalol enhanced sIPSCs by a presynaptic mechanism, increasing GABA release.
3.3.
Selective β 1 -adrenoceptor blockade mimics labetalol-induced facilitation of GABA release Labetalol has antagonistic effects on α 1 -, β 1 -and β 2 -adrenoceptors. We observed that a β 1 -adrenoceptor antagonist (metoprolol) facilitated sIPSC frequency, while the antagonists of α 1 -and β 2 -adrenoceptors decreased sIPSC frequency. Furthermore, 100 nM metoprolol diminished, and 10 μM metoprolol abolished, labetalol-induced enhancement of GABA release. These results indicated that labetalol shares the same pathway as metoprolol in enhancing GABA release via blockade of β 1 -adrenoceptors. Our observation is also consistent with previous studies that showed that the potency of labetalol for β-adrenergic blockade is fivefold to tenfold of that for α-adrenergic blockade (see Blakeley and Summers, 1977; Drew et al., 1978; Gold et al., 1982) .
3.4.
Labetalol-induced enhancement of GABAergic inhibition of PAG neurons might contribute to its analgesic effect
We showed that PAG neurons were under the tonic control of GABAergic neurons, as evidenced by the spontaneous GABAergic IPSCs recorded from the PAG neurons. Furthermore, application of bicuculline, a GABA A receptor antagonist, eliminated all sIPSCs and markedly enhanced the frequency of spontaneous firings of PAG neurons. We additionally showed that labetalol alone inhibited spontaneous firing in PAG neurons. Interestingly, the application of bicuculline did significantly attenuate (by> 50%) labetalol-induced inhibition of the firing of PAG neuron. This suggests that the enhancement of GABA release, at least partially, contributes to labetalol-induced inhibition of cell firing, although there could be some other underlying mechanisms, which warrant further investigations.
Noradrenergic receptors modulate the physiological response to a painful stimulation. Previous studies have focused more on α-adrenoceptors than on β-adrenoceptors. The clinical influence, of β-blockers upon anesthesia and postoperative pain, has been examined in few previous studies. Stanley et al. (1982) showed a reduction, in sufentanil requirements for unconsciousness, in patients receiving chronic propranolol treatment before coronary-artery bypass surgery. The use of β-antagonists has been found to reduce anesthetic requirements during anesthesia (Johansen et al., 1997) , to reduce inhalation anesthetic MAC (minimal alveoli concentration), and to improve postoperative recovery (Zaugg et al., 2002) . In a recent clinical study of patients undergoing hysterectomy, Chia and colleagues (2004) found that the use of the perioperative β-antagonist, esmolol, administration during anesthesia, reduced the intraoperative use of inhalation anesthetics and fentanyl. Esmolol use also decreased sympathetically mediated hemodynamic responses. Furthermore, it reduced morphine consumption for the first 3 postoperative days.
It has been suggested that perioperative β-antagonist administration is an alternative to remifentanil, a short-acting μ-opioid receptor agonist, in maintaining stable intraoperative hemodynamics (Coloma et al., 2001) . However, the specific mechanism, by which β-adrenoceptor blockers potentiate the analgesic effects of an opioid, or an inhalation anesthetic, remains controversial (Chia et al., 2004) . Our data may provide an interpretation for these observations that both opioid agents and β-adrenoceptor blockers inhibit PAG neuron activity and interrupt pain transmission.
It is important to emphasize the limitations to the approach we have taken. First, we only used norepinephrine in the presence of α-and β 2 -receptor blockade to enhance IPSC frequency as evidence of β 1 receptor involvement. Future study using a more specific β 1 agonist to verify the current result is warranted. However, as metoprolol mimics the effect of labetalol on sIPSCs, this result enables us to demonstrate the involvement of β 1 receptors in labetalol-induced facilitation of GABAergic transmission. Second, the principle cellular action of β agonists acting through guanine nucleotide binding (G) proteins Gs is to stimulate cAMP formation. Increased cAMP formation in the PAG and elsewhere profoundly (many-fold) enhances probability of GABA release events. The opposite was found in the current study. Future study is necessary to investigate the biochemical mechanism of enhanced GABA release by labetalol, to determine whether labetalol affects the protein kinase A pathways, etc.
In conclusion, we have demonstrated that functional α 1 -, β 1 -and β 2 -adrenoceptors exist on GABA-releasing terminals which make synapses onto PAG neurons. These presynaptic adrenoceptors are tonically activated. It is suggested that labetalol inhibits presynaptic β 1 -adrenoceptors, leading to an increased release of GABA and subsequent an inhibition of PAG neuronal activity. This may contribute to the analgesic effects of labetalol observed in vivo. Future studies are warranted to determine whether other β 1 -adrenoceptor antagonists also have an effect similar to that of labetalol shown in current investigation.
4.
Experimental procedures
Slice preparation and mechanical dissociation
The care and use of animals, and the experimental protocol, were approved by the Institutional Animal Care and Use Committee of the University of Medicine and Dentistry of New Jersey. The experiments were done on PAG neurons from 2-to 4-week old Sprague Dawley rats. The midbrain slices were prepared as described previously (Ye et al., 2006) . In brief, rats were decapitated, and the brain was quickly excised and coronally sliced (300 μm) with a VF-200 Slicer (Precisionary Instruments, Greenville, NC). This was done in ice-cold glycerol-based artificial cerebrospinal fluid (GACSF) -containing (in mM) 250 glycerol, 1.6 KCl, 1.2 NaH 2 PO 4 , 1.2 MgCl 2 , 2.4 CaCl 2 , 25 NaHCO 3 , and 11 glucose, and saturated with 95%O 2 /5%CO 2 (carbogen) (Ye et al., 2006) . Midbrain slices were then kept in carbogen-saturated regular ACSF, in which the glycerol was replaced by 125 mM NaCl, at room temperature (22 -24°C) for at least 1 h before use.
PAG neurons with functional terminals attached were isolated from the ventrolateral region of PAG area of midbrain slices using an enzyme-free mechanical dissociation procedure, as previously described (Akaike and Moorhouse, 2003; Ye et al., 2004) . Briefly, midbrain slices were kept in carbogensaturated ACSF at room temperature (22-24°C) for at least 1 h before mechanical dissociation. The slice was then transferred to a 35 mm culture dish (Falcon, Rutherford, NJ) filled with a standard external solution containing (in mM): 140 NaCl, 5 KCl, 2 CaCl 2 , 1 MgCl 2 , 10 HEPES, and 10 Glucose (320 mOsm, pH set to 7.3 with Tris base). Under an inverted microscope (Nikon, Tokyo, Japan), PAG was identified. A heavily fire-polished glass micropipette was placed on the surface of the ventrolateral region of the PAG. This tip of the pipette was vibrated horizontally, at ∼ 20 Hz for 2 -5 min by a homemade device. The slice was then removed. The liberated neurons were left to settle onto the base of the dish within 20 min. The fusiform or pyramidal neurons (Fig. 1C, D) , with diameters greater than 15 μm were selected for electrophysiological recording.
The experimental procedure for recording from brain slices was similar to what has been described recently (Xiao et al., 2007; Ye et al., 2004; Wang et al., 2005) . Briefly, slices (two per animal) were transferred in a 0.4 ml recording chamber and stabilized with a U-shaped stainless steel net. Cells were visualized using an upright microscope with near-infrared illumination (E600FN, Nikon, Japan) (Fig. 1B) . Throughout the experiments, the bath was continually superfused with carbogen-saturated ACSF at a rate of 2 -3 ml/min.
Electrophysiological recording
Whole-cell currents were recorded with Axopatch 200B and 700A amplifiers (Molecular Devices Co., Union City, CA, USA), via Digidata 1320A and 1322A analog-to-digital converters (Molecular Devices Co.), and pClamp 9 software (Molecular Devices Co). Data were sampled at 5 kHz and filtered at 1 kHz. Whole-cell recordings were made 5 -7 min after the patched membrane was ruptured. This was in consideration of the equilibration of the gradients between the pipette solution and the cytoplasm. The patch electrodes had a resistance of 3 -5 MΩ when filled with pipette solutions containing (in mM): 140 KCl, 2 MgCl 2 , 4 EGTA, 0.4 CaCl 2 , 10 HEPES, 2 Mg-ATP, and 0.1 GTP (for voltageclamp experiments), or 135 potassium gluconate, 5 KCl, 2 MgCl 2 , 10 HEPES, 2 Mg-ATP, and 0.2 GTP (for current clamp experiments). The pH was adjusted to 7.2 with Tris base, and the osmolarity was adjusted to 280 -300 mOsm with sucrose.
Chemicals and applications
Most of the chemicals, including bicuculline (BIC), adenosine 5′-triphosphate (ATP), guanine 5′-triphosphate (GTP), DL-2-amino-5-phosphono-valeric acid (DL-APV), 6,7-dinitroquinoxaline-2, 3-dione (DNQX), prazosin, and butoxamine were purchased from Sigma (St. Louis, MO). Labetalol, metoprolol, phentolamine, and norepinephrine were from Bedford Laboratories (Bedford, OH). Chemicals were applied, to dissociated neurons, with a Y-tube perfusion system. With this system, the external solution, surrounding the neurons could be exchanged within 40 ms. In experiments on brain slices, chemicals were prepared in the final concentration in ACSF, and were applied via bath perfusion. The fact that 10 μM bicuculline blocked spontaneous inhibitory postsynaptic currents (sIPSCs) within 90 s is an indication of the effective bath exchange time (Ye et al., 2004) .
Data analysis
The sIPSCs were counted and analyzed using Clampfit 9.2 software (Molecular Devices Corp, Sunnyvale, CA, USA). The sIPSCs were screened automatically using a template with an amplitude threshold of 5 pA and then visually accepted or rejected based upon their 10-90% rise and 90-37% decay times. The majority (above 95%), of those sIPSCs, which were visually accepted, were screened using a suitable template. The frequency and amplitude of all events, during and after drug applications, were normalized to the mean values obtained during the control period. The inter-event intervals and amplitudes of sIPSCs obtained from the same neuron were examined by constructing cumulative probability distributions, and these distributions under different experimental conditions were compared using the Kolmogorov-Smirnov (K -S) test with Clampfit 9.2. For other plots, the frequency and amplitude of all events over 1-2 min during the peak of a drug response were normalized to the average values of those during the initial control period (5-10 min). A concentration response curve was fitted with a Logistic equation: y = A 2 + (A 1 − A 2 ) / (1 + (x / x 0 ) p ), where y is the drug-elicited percentage change, of the frequency of sIPSCs, compared to control. A 1 is the minimum effect and A 2 is the maximum effect. X 0 and p denote the half-effective concentration (EC 50 ) and Hill coefficients, respectively. Differences in amplitude and frequency were tested by Student's paired two-tailed t-test using their normalized values. Numerical values were provided as the mean ± standard error of the mean (SEM). Values of p < 0.05 were considered significant.
